ECSP13013117A - Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina. - Google Patents

Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.

Info

Publication number
ECSP13013117A
ECSP13013117A ECSP13013117A ECSP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A EC SP13013117 A ECSP13013117 A EC SP13013117A
Authority
EC
Ecuador
Prior art keywords
methods
multiple sclerosis
reducing
content
myeline
Prior art date
Application number
Other languages
English (en)
Inventor
Katherine Dawson
Neill Gllmore O
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013117(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of ECSP13013117A publication Critical patent/ECSP13013117A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para tratar la esclerosis múltiple en un sujeto, que incluyen: reducir la frecuencia de recidiva, reducir la tasa de recidiva anualizada, reducir el riesgo de la evolución de la discapacidad, reducir el número de lesiones en T2 recientes o recientemente aumentadas, reducir el número de lesiones del gadolinio; y métodos para preservar/aumentar el contenido de mielina en un sujeto que tiene esclerosis múltiple al administrar diariamente una composición que contiene un fumarato, tal como fumarato de dimetilo o fumarato de monometilo, al sujeto.
ECSP13013117 2011-05-26 2013-12-26 Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina. ECSP13013117A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
ECSP13013117A true ECSP13013117A (es) 2014-06-30

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013117 ECSP13013117A (es) 2011-05-26 2013-12-26 Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.

Country Status (19)

Country Link
US (1) US20140163100A1 (es)
EP (1) EP2713724A4 (es)
JP (1) JP2014515373A (es)
KR (1) KR20140036257A (es)
CN (1) CN103732062A (es)
AU (1) AU2012258558A1 (es)
BR (1) BR112013030169A2 (es)
CA (1) CA2836480A1 (es)
CL (1) CL2013003358A1 (es)
CO (1) CO6811862A2 (es)
EA (1) EA201391578A1 (es)
EC (1) ECSP13013117A (es)
IL (1) IL229448A0 (es)
MX (1) MX2013013781A (es)
PE (1) PE20141316A1 (es)
PH (1) PH12013502443A1 (es)
SG (1) SG195049A1 (es)
WO (1) WO2012162669A1 (es)
ZA (1) ZA201308681B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004010531T2 (de) 2003-09-09 2008-07-03 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
EP3470064A1 (en) 2004-10-08 2019-04-17 Fwp Ip Aps Controlled release pharmaceutical compositions comprising a fumaric acid ester
NZ608196A (en) 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
MX355421B (es) 2011-06-08 2018-04-18 Biogen Ma Inc Proceso para preparar fumarato de dimetilo cristalino y de alta pureza.
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
EP3566701A1 (en) 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
ES2955137T3 (es) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9326965B2 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
AU2014414316B2 (en) * 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102590068B1 (ko) 2014-12-11 2023-10-16 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1951206A1 (en) * 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
PT2653873T (pt) * 2007-02-08 2022-07-26 Biogen Ma Inc Composições e utilizações para o tratamento de esclerose múltipla
LT2139467T (lt) * 2007-02-08 2016-10-10 Biogen Ma Inc. Neuroapsauga, sergant demielinizuojančia liga
NZ608196A (en) * 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
CN102427727A (zh) * 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗

Also Published As

Publication number Publication date
PE20141316A1 (es) 2014-10-01
CL2013003358A1 (es) 2014-08-01
US20140163100A1 (en) 2014-06-12
MX2013013781A (es) 2014-01-08
AU2012258558A1 (en) 2013-05-02
BR112013030169A2 (pt) 2016-08-09
KR20140036257A (ko) 2014-03-25
WO2012162669A1 (en) 2012-11-29
SG195049A1 (en) 2013-12-30
EP2713724A1 (en) 2014-04-09
EA201391578A1 (ru) 2014-05-30
EP2713724A4 (en) 2015-03-11
IL229448A0 (en) 2014-01-30
CO6811862A2 (es) 2013-12-16
JP2014515373A (ja) 2014-06-30
CA2836480A1 (en) 2012-11-29
CN103732062A (zh) 2014-04-16
ZA201308681B (en) 2017-11-29
PH12013502443A1 (en) 2019-03-22

Similar Documents

Publication Publication Date Title
ECSP13013117A (es) Métodos para tratar la esclerosis múltiple y preservar y/o aumentar el contenido de mielina.
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
PH12014501639A1 (en) Pharmaceutical compositions and methods
MX2013003076A (es) Terapeuticos contra cancer de mama.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
PH12014501032A1 (en) 2-thiopyrimidinones
CO6731092A2 (es) Nueva forma de administración de inhibidor de encefalinasa
MX356025B (es) Uso de glicopirrolato para tratar taquicardia.
MX357510B (es) Metodos para tratar ataques de gota.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib
MX337139B (es) Composicion de miel con l-alanil-l-glutamina.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
AR084169A1 (es) Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
Trainor Broome Taxi rides
IN2014KN01142A (es)
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek